Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.8% – Here’s Why

Shares of Twist Bioscience Co. (NASDAQ:TWST) were down 5.8% on Monday . The company traded as low as $49.12 and last traded at $49.26. Approximately 125,025 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 769,663 shares. The stock had previously closed at $52.30.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TWST. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Robert W. Baird increased their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Scotiabank upped their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 4th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Price Performance

The company has a 50-day moving average of $48.79 and a 200-day moving average of $45.99. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same period in the prior year, the business posted ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. Analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares of the company’s stock, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,180 shares of company stock valued at $1,821,971. 3.01% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Van ECK Associates Corp increased its position in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the 3rd quarter worth $34,000. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. US Bancorp DE lifted its position in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the third quarter worth about $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.